Company Filing History:
Years Active: 2021-2023
Title: Catherine Regnier: Innovator in Monoclonal Antibodies
Introduction
Catherine Regnier is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of immunology through her innovative work on humanized monoclonal antibodies. With a total of 2 patents, her research focuses on enhancing immune responses.
Latest Patents
Catherine's latest patents include "Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof." This invention relates to antibodies that bind to human interleukin-2 (hIL-2). More specifically, it involves humanized antibodies that target a particular epitope of hIL-2. When these antibodies bind to this epitope, they exhibit a unique capability of inhibiting the binding of hIL-2 to CD25.
Career Highlights
Catherine Regnier is affiliated with Universität Zürich, where she continues her research and development in the field of immunology. Her work has garnered attention for its potential applications in therapeutic settings.
Collaborations
Catherine collaborates with notable colleagues, including Natalia Arenas-Ramirez and Iwan Beuvink. These partnerships enhance her research efforts and contribute to the advancement of her innovative projects.
Conclusion
Catherine Regnier stands out as an influential inventor in the realm of monoclonal antibodies, with her work promising to impact the field of immunology significantly. Her dedication to research and collaboration continues to drive innovation forward.